{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:29:17Z","timestamp":1759332557235,"version":"3.40.5"},"reference-count":9,"publisher":"FapUNIFESP (SciELO)","issue":"3 suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An. Bras. Dermatol."],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1590\/abd1806-4841.20153672","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T22:44:01Z","timestamp":1440024241000},"page":"165-167","source":"Crossref","is-referenced-by-count":8,"title":["New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus"],"prefix":"10.1590","volume":"90","author":[{"given":"Victor Pavan","family":"Pasin","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Regio","family":"Pereira","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalline Andrade de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Marcos G\u00f3es de","family":"Paiva","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milvia Maria Sim\u00f5es e Silva","family":"Enokihara","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Maria","family":"Porro","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s00520-013-1826-3","article-title":"Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial","volume":"21","author":"Peterson ME","year":"2013","journal-title":"Support Care Cancer"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins F","year":"2013","journal-title":"Oral Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.ejca.2011.03.017","article-title":"Natural history, management and pharmacokinetics of Everolimus induced-oral ulcers: Insights into compliance issues","volume":"47","author":"Fert\u00e9 C","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review","volume":"17","author":"Boers-Doets CB","year":"2012","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee WJ","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje SA","year":"2011","journal-title":"Target Oncol"},{"key":"ref7","first-page":"149","article-title":"Clin","volume":"24","author":"Campistol JM","year":"2010","journal-title":"Transplant"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/TP.0b013e31825b411c","article-title":"A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian Target of Rapamycin Inhibitor","volume":"94","author":"Gurk-Turner C","year":"2012","journal-title":"Transplantation"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","article-title":"Atazanavir for the treatment of human immunodeficiency virus infection","volume":"24","author":"Busti AJ","year":"2004","journal-title":"Pharmacotherapy"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abd\/v90n3s1\/0365-0596-abd-90-03-s1-0165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:43Z","timestamp":1747666843000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0365-05962015000700165&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":9,"journal-issue":{"issue":"3 suppl 1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0365-05962015000700165"],"URL":"https:\/\/doi.org\/10.1590\/abd1806-4841.20153672","relation":{},"ISSN":["0365-0596"],"issn-type":[{"type":"electronic","value":"0365-0596"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}